Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15044040 | 1.00 | LMNA (0.37) | LMNATHRBTSHRL3MBTL1TDP1 | |
| SCHEMBL15895084 | 1.00 | LMNA (0.37) | LMNATHRBTSHRL3MBTL1TDP1 | |
| SCHEMBL14556007 | 0.94 | LMNA (0.38) | LMNATHRBTSHRL3MBTL1TDP1 | |
| SCHEMBL15484277 | 0.85 | THRB (0.44) | LMNATHRBL3MBTL1TDP1 | |
| SCHEMBL4956291 | 0.84 | PTPN1 (0.37) | LMNATSHR | |
| SCHEMBL6436093 | 0.83 | LMNA (0.48) | LMNATHRBTSHRL3MBTL1TDP1 | |
| SCHEMBL8855937 | 0.82 | — | — | |
| SCHEMBL8855929 | 0.82 | — | — | |
| SCHEMBL395052 | 0.82 | — | — | |
| SCHEMBL3174122 | 0.82 | LMNA (0.38) | LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160296630-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPIES | ENDOCYTE INC (US) | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296630-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPIES | SLC7A11, CXCR2, TPX2 | LMNA 4453/4885THRB 878/4885TSHR 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.